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Abstract
Tumor-associated and tumor-infiltrating neutrophils (TAN)
and macrophages (TAM) can account for as much as 50% of
the total tumor mass in invasive breast carcinomas. It is
thought that tumors secrete factors that elicit a wound-
repair response from TAMs and TANs and that this response
inadvertently stimulates tumor progression. Oncostatin M is
a pleiotropic cytokine belonging to the interleukin-6 family
that is expressed by several cell types including activated
human T lymphocytes, macrophages, and neutrophils.
Whereas oncostatin M can inhibit the proliferation of
breast cancer cells in vitro , recent studies suggest that
oncostatin M may promote tumor progression by enhancing
angiogenesis and metastasis. In addition, neutrophils can be
stimulated to synthesize and rapidly release large quantities
of oncostatin M. In this article, we show that human
neutrophils secrete oncostatin M when cocultured with
MDA-MB-231 and T47D human breast cancer cells. Neutro-
phils isolated from whole blood or breast cancer cells alone
express little oncostatin M by immunocytochemistry and
ELISA, but neutrophils express and release high levels of
oncostatin M when they are cocultured with breast cancer
cells. In addition, we show that granulocyte-macrophage
colony-stimulating factor produced by breast cancer cells
and cell-cell contact are both necessary for the release of
oncostatin M from neutrophils. Importantly, neutrophil-
derived oncostatin M induces vascular endothelial growth
factor from breast cancer cells in coculture and increases
breast cancer cell detachment and invasive capacity,
suggesting that neutrophils and oncostatin M may promote
tumor progression in vivo. (Cancer Res 2005; 65(19): 8896-904)
Introduction
Neutrophils, also known as polymorphonuclear leukocytes,
represent 50% to 60% of the total circulating leukocytes and
constitute the first line of defense against infectious agents or
‘‘nonself ’’ substances that penetrate the body’s physical barriers.
Neutrophils form a primary defense against bacteria, fungi,
protozoa, viruses, and virally infected cells and also target
tumor cells (1). In the blood stream, inactivated neutrophils are
short-lived (8 hours), terminally differentiated cells, that under
conditions of inflammation are able to survive for longer periods of
time and can up-regulate a variety of cytokines (2) including
interleukin-1h (IL-1h), IL-6, IL-8, tumor necrosis factor-a, granu-
locyte macrophage colony-stimulating factor (GM-CSF; ref. 1), and
oncostatin M (3). Oncostatin M is not secreted in significant
amounts by resting neutrophils but is produced in response to
inflammatory mediators (4–6), and the tumor-infiltrating neutro-
phil population was originally identified as a primary source of
oncostatin M (7). Human neutrophils have the capacity to direct
the progression of an inflammatory reaction by influencing the
activity of other immune cells and tissues (5).
Tumor-associated neutrophils (TAN) have been shown to
promote tumor progression via a variety of mechanisms, including
the stimulation of angiogenesis and invasion (8). TANs can also
stimulate tumor growth by releasing growth factors such as
epidermal growth factor, transforming growth factor-h (TGF-h),
and platelet-derived growth factor (PDGF; ref. 9). In fact, it is
thought that tumors secrete factors that elicit a wound-repair
response from TANs and tumor-associated macrophages and
that this response inadvertently stimulates tumor progression
(10). TANs have been detected in adenocarcinoma of the
bronchioloalveolar carcinoma (BAC) subtype (11) and in colon
(12) and ovarian cancer4 by immunohistochemistry. Wislez et al.
(11) have shown that tumor cells drive local neutrophil recruit-
ment and persistence in the lung via cytokine release, and this
increase in TANs are linked to poorer outcome of patients with
BAC subtype.
Oncostatin M is a 28-kDa pleiotropic cytokine of the IL-6
family (13) that is a product of activated T lymphocytes (14),
monocytes (15), neutrophils (4), and some tumor cells including
breast cancer epithelial cells (16). Oncostatin M has been shown to
exert proinflammatory effects by inducing adhesion and chemo-
taxis of neutrophils and chemokine production by endothelial cells
(17, 18). Although oncostatin M was originally identified as an
inhibitor of melanoma tumor cell growth in vitro (19) and has been
shown to inhibit breast cancer cell proliferation in vitro (14), it is
increasingly apparent that this cytokine plays a role in breast
cancer cell detachment (20) and angiogenesis.5 These results
suggest that oncostatin M may enhance tumor progression and
metastasis in vivo .
Oncostatin M–specific receptors are expressed in a wide variety
of cell types, including endothelial, hepatic, lung, bone marrow
cells, and many tumor cell lines (21–23). Oncostatin M elicits its
biological effects through two types of transmembrane receptors:
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the type I oncostatin M receptor is identical to the high-affinity
leukemia inhibitory factor (LIF) receptor, composed of gp130 and
LIFRh, and the type II oncostatin M receptor, composed of gp130
and the oncostatin M–specific receptor h subunit (OSMRh which is
specific for oncostatin M; refs. 21, 22). Oncostatin M can signal
through the Janus-activated kinase/signal transducer and activator
of transcription (JAK-STAT) pathway (7), the mitogen-activated
protein kinase pathway (14, 24), and the phosphatidylinositol 3-
kinase pathway (25).
Angiogenesis, the growth of new blood vessels from a preexisting
microvascular bed (26), is crucial for the growth, maintenance, and
metastasis of solid tumors (26, 27). When tumor cells and/or
tumor-associated stromal and inflammatory cells express proan-
giogenic molecules, the normal, neutral balance of proangiogenic
and antiangiogenic factors is disrupted, such that angiogenesis is
initiated (28). The association of neutrophils with certain tumors
and the ability of neutrophils to secrete a variety of proinflamma-
tory cytokines make these cells ideally situated to influence
angiogenesis and tumor progression.
Depending on the cytokine milieu in which they act, TANs may
promote tumor progression by secreting growth factors (TGF-h,
PDGF, and oncostatin M; ref. 7), angiogenic factors (vascular
endothelial growth factor or VEGF, hepatocyte growth factor, and
IL-8; ref. 9), and matrix-degrading enzymes (elastase and cathepsin
G; ref. 9). However, which factors secreted by neutrophils play a
role in breast tumor progression remains unclear. Here we have
focused on the cytokine oncostatin M and invasive breast cancer.
Using an in vitro model, we have examined the expression of
oncostatin M by neutrophils in the presence and absence of breast
cancer cells and asked whether oncostatin M can influence the
invasive capacity of breast cancer cells. Our results show that
freshly isolated human neutrophils express little oncostatin M until
‘‘primed’’ with human breast cancer conditioned medium. Oncos-
tatin M production by neutrophils can be inhibited by the addition
of anti-GM-CSF-neutralizing antibody to the conditioned medium
before priming the neutrophils. Cell-to-cell contact is required for
oncostatin M release from neutrophils. This neutrophil-derived
oncostatin M signals human breast cancer cells to secrete VEGF
and increases breast cancer cell detachment and invasive capacity.
Our findings could provide grounds for the development of cancer
therapies designed to inhibit oncostatin M release from leukocytes.
Materials and Methods
Breast cancer cell conditioned medium. MDA-MB-231 and T47D
human breast cancer cells were plated in RPMI (Life Technologies, Inc.,
Grand Island, NY) + 10% fetal bovine serum (FBS, Life Technologies) at
37jC, 5% CO2. Once cells were 40% to 60% confluent, the medium was
removed, cells were washed with PBS, and RPMI + 1% FBS was added for
48 hours. After 48 hours, the medium was collected, centrifuged, and
conditioned medium was transferred to a new tube. Conditioned medium
was then stored at20jC and used in all experiments to prime neutrophils
unless described otherwise.
Purification of neutrophils. Blood was collected from healthy human
volunteers by venipuncture into heparin-coated vacutainers. Ten to 20 mL
of fresh blood were carefully layered over a histopaque column (5 mL 1119
and 5 mL 1077; Sigma-Aldrich, St. Louis, MO) and then centrifuged. After
centrifugation at 700  g for 30 minutes (18-22jC), bands for plasma,
platelets, granulocytes, and erythrocytes were visible. The lower band
consisted primarily of neutrophils and was transferred to a new tube and
diluted by addition of one volume of 1 PBS (Sigma-Aldrich) solution.
Collected cells were centrifuged at 300  g for 10 minutes (18-22jC)
and washed in 9 mL of distilled water for 20 seconds to lyse remaining
RBC. One milliliter of 10 PBS (Sigma) without calcium was added, and
cells were centrifuged again, followed by resuspension in conditioned
medium.
Neutrophil priming. Freshly isolated neutrophils were placed in the
appropriate breast cancer cell conditioned medium (either MDA-MB-231
or T47D) for 18 to 24 hours, for priming, before coculturing with either
cell lines. Neutrophil priming increased cell survival by allowing
neutrophils to adjust to their environment before being plated with
breast cancer cells (29).
Breast cancer cell and neutrophil coculture. Primed neutrophils were
counted with a hemacytometer (American Optical, Buffalo, NY) and plated
at a concentration of 2.5  105 cells/mL along with breast cancer cells in
RPMI + 1% FBS.
Immunocytochemistry for oncostatin M. Human breast cancer cells
were plated in a 24-well dish with or with out fresh neutrophils in RPMI +
1% FBS for 24 hours. After incubation, breast cancer cells were scraped off
the bottom of the 24-well dish with the side of a pipette tip, and the
medium containing both the neutrophils and breast cancer cells was
collected. The medium was centrifuged at 12,000 rpm for 2 minutes and the
cells were resuspended in 300 AL serum-free RPMI. Thirty-five percent
bovine serum albumin (80 AL; Life Technologies) was added to the cell
suspension before cytospinning. Samples were placed in a cytospin chamber
(Shannon Southern Instruments, Sewickley, PA) and spun onto slides for
10 minutes at 800 rpm. Slides were allowed to air-dry and were
immunostained with anti-oncostatin M antibody (Chemicon, Temecula,
CA) at 1:100 dilution for 24 hours at 4jC using 3,3V-diaminobenzidine as a
substrate (Zymed Laboratories, Inc., San Francisco, CA), as per protocol.
Images were taken with an Olympus IX70 inverted microscope (Olympus
America, Inc., Melville, NY; 400; light).
Oncostatin M ELISA. Oncostatin M ELISAs (R&D Systems, Minneapolis,
MN) were done according to the manufacturer’s protocol. The absorbance
was recorded using a microplate reader (Bio-Rad, Hercules, CA) at 450-nm
wavelength.
To access a role for GM-CSF, neutrophils were primed in conditioned
medium with or with out 10 Ag/mL anti-GM-CSF-neutralizing antibody
(R&D Systems) for 18 to 24 hours and primed neutrophils cocultured with
human breast cancer cellsF anti-GM-CSF-neutralizing antibody (10 Ag/mL).
Sample medium was collected at 15-minute, 1-, 12-, and 24-hour time points
and analyzed by oncostatin M ELISA.
To determine neutrophil granule release, primed neutrophils were
cocultured with breast cancer cells F formylated methionine-leucine-
phenylalanine (FMLP, 5  107 mol/L). As a control, neutrophils alone were
plated F FMLP (5  107 mol/L). Medium was collected at 15-minute,
1-, 12-, and 24-hour time points and analyzed by oncostatin M ELISA.
Cell-to-cell contact was analyzed by plating primed neutrophils in the
lower chamber of a 24-well transwell dish (BD Biosciences, Bedford, MA) in
RPMI + 1% FBS. A transwell insert (3 Am) containing human breast cancer
cells in RPMI + 1% FBS was added and incubated for 24 hours. Medium
from the upper and the lower chamber of the transwell insert was collected,
combined, and analyzed using an oncostatin M ELISA.
Three independent experiments were done for each experiment with
each data point representing six replicates. SDs were calculated and error
bars represent FSD.
Vascular endothelial growth factor ELISA. VEGF ELISAs (Cytimmune
Science, Inc., Rockville, MD) were done according to the manufacturer’s
protocol. The absorbance was recorded using a microplate reader (Bio-Rad)
at 490-nm wavelength.
Breast cancer cells (MDA-MB-231 or T47D) were plated with 0.1 Ag/mL
anti-OSMRh-neutralizing antibody (Amgen, Inc., Thousand Oaks, CA),
0.1 Ag/mL anti-LIFRh-neutralizing antibody (R&D Systems), 0.1 Ag/mL
anti-gp130-neutralizing antibody (R&D Systems), or 0.1 Ag/mL of both
anti-OSMRh- and anti-LIFRh-neutralizing antibodies, 1 hour before the
addition of primed neutrophils and plated in RPMI + 1% FBS, incubated
for 72 hours, and collected medium was analyzed using the VEGF ELISA.
Three independent experiments were done with each data point
representing six replicates. SDs were calculated and error bars repre-
sent F SD.
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Breast cancer cell detachment. Human MDA-MB-231 and T47D breast
carcinoma cells were plated on uncoated six-well plates in RPMI + 10%
FBS. After the cells had grown to f60% to 70% confluency, the medium
was removed and 2.5  105 cells/mL primed neutrophils were added in
1 mL serum-free medium. The following treatments were done: breast
cancer cells alone, breast cancer cells plated with primed neutrophils, or
breast cancer cells plated with primed neutrophils pretreated with
oncostatin M–neutralizing antibody (50 Ag/mL) 1 hour before plating.
Cultures were incubated for 2, 4, and 6 days, and images were collected
using a Zeiss Axiovert25 Microscope (400, phase contrast). In addition,
detached and adherent cells were collected at each time point and
counted with a hemacytometer (American Optical, Buffalo, NY).
Detachment was expressed as a percentage of total number of cells and
calculated using the following equation: % detachment = detached cells /
[total cells (detached cells + adherent cells)]. Viability of detached cells
was assessed by trypan blue exclusion. Four independent experiments
were done with each data point representing eight replicates. SDs were
calculated and error bars represent F SD.
Invasion assay. Matrigel-coated invasion chambers (BD Biosciences,
Bedford, MA) were thawed and allowed to rehydrate for 2 hours with
serum-free RPMI at 37jC. After rehydration, medium was removed and
RPMI + 15% FBS (as a chemoattractant) was added to the lower
chamber. Breast cancer cells were plated with or without neutrophils in
RPMI + 1% FBS in the upper chamber. Neutophils cocultured with breast
cancer cells were also plated with and without 50 Ag/mL (single dose at
time 0) of anti-oncostatin M–neutralizing antibody. Cells were then
incubated for 22 hours and then a cotton swab was used to remove the
noninvading cells from the upper chamber. The Matrigel-coated inserts
were fixed in 100% methanol for 2 minutes and stained in 1% toluidine
blue, 1% borax in PBS for 2 minutes. Stained inserts were rinsed in
distilled water and allowed to air-dry. Invading cells were counted using
a Zeiss Axiovert25 Microscope (200, light) and percent invasion was
calculated. Percent invasion was calculated by the following equation:
% invasion = [mean no. of cells invading through Matrigel insert
membrane / mean no. of cells migrating through control insert
membrane (inserts without Matrigel coating)]  100. Five independent
experiments were done with each data point representing 10 replicates.
SDs were calculated and error bars represent F SD.
Results
Neutrophils cocultured with human breast cancer cells
express oncostatin M. Freshly isolated (nonprimed) neutrophils
express no oncostatin M versus neutrophils that had been
primed with conditioned medium for 18 to 24 hours (Fig. 1A),
as detected by immunocytochemistry. Little or no oncostatin M
expression was detected in MDA-MB-231 (highly metastatic) or
T47D (weakly metastatic) human breast cancer cells cultured alone
at 24 hours (Fig. 1A). Coculture of freshly isolated neutrophils with
MDA-MB-231 or T47D cells for 24 hours induced expression of
oncostatin M, as indicated by brown staining within neutrophils
surrounding each particular cancer cell (Fig. 1A). Cocultured T47Ds
have a slight brown staining that may be due to the fact that both
T47D and MDA-MB-231 human breast cancer cells make and
secrete small amounts of oncostatin M. This staining was not seen
in the absence of anti-oncostatin M antibody (secondary antibody
alone; Fig. 1A). Neutrophils showed multi-lobed nuclei by
hematoxylin staining (Fig. 1A).
Freshly isolated neutrophils primed overnight with conditioned
medium from MDA-MB-231 or T47D human breast cancer cells
showed low levels of oncostatin M secretion by ELISA, as did breast
cancer cells cultured alone (Fig. 1B-C). A time course of cocultured
cells indicated a relatively rapid release of oncostatin M from
neutrophils by 15 minutes, which was sustained over time with
MDA-MB-231 cells (Fig. 1B) and decreased over time with T47D
cells (Fig. 1C). Our findings indicate that neutrophils cocultured
Figure 1. Neutrophils cocultured
with human breast cancer cells
express oncostatin M (OSM ).
A, immunocytochemistry of freshly isolated
nonprimed neutrophils stained with
anti-oncostatin M antibody shows no
oncostatin M expression, whereas
neutrophils primed in conditioned medium
(CM) show some oncostatin M expression
(brown staining). MDA-MB-231 and T47D
human breast cancer cells cultured alone
express little oncostatin M. Freshly isolated
neutrophils cocultured 24 hours with
MDA-MB-231 and T47D cells express
increased levels of oncostatin M. During
coculture, MDA-MB-231 cells show little
oncostatin M expression and T47D
cells show slightly more oncostatin M
expression. Neutrophils cocultured with
MDA-MB-231 or T47D human breast
cancer cells show no staining with
secondary (2j) antibody alone.
Hematoxylin-stained neutrophils show
multilobed nuclei. MDA-MB-231 (B )
and T47D (C ) human breast cancer
cells cocultured with neutrophils secrete
increased levels of oncostatin M compared
with breast cancer cells or neutrophils
cultured alone, as measured by ELISA.
Time course analysis shows highest
amounts of secreted oncostatin M by
15 minutes, suggesting a granular release
of presynthesized oncostatin M.
Cancer Research
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with human breast cancer cells secrete increased levels of
oncostatin M compared with neutrophils alone.
Granulocyte-macrophage colony-stimulating factor signals
accumulation of granule-stored oncostatin M. We have found
by immunocytochemistry that freshly isolated human neutrophils
express little oncostatin M, yet upon ‘‘priming’’ 18 to 24 hours in
conditioned medium from human breast cancer cells, they
acquire the ability to secrete oncostatin M. We investigated what
factor in the conditioned medium was responsible for oncostatin
M accumulation. Wu et al. (29) found that MDA-MB-231 breast
cancer cells produced high levels of GM-CSF, and we sought to
determine whether GM-CSF secreted from human breast cancer
cells was the signal for neutrophils to produce and secrete
oncostatin M. To block GM-CSF in breast cancer conditioned
medium, anti-GM-CSF-neutralizing antibody (50 Ag/mL) was
added 1 hour before neutrophil priming relative to normally
primed neutrophils. Neutrophils primed in conditioned medium
plus anti-GM-CSF antibody and cocultured with MDA-MB-231
human breast cancer cells secreted significantly less oncostatin M
(5.8-fold decrease) at 15 minutes by ELISA (Fig. 2A), similar to the
amount of oncostatin M secreted by MDA-MB-231 cells or
neutrophils cultured alone. When normally primed neutrophils
were cocultured with MDA-MB-231 cells, and anti-GM-CSF-
neutralizing antibody was added only at the time of plating, the
levels of oncostatin M secretion decreased slightly (1.3-fold;
Fig. 2A), suggesting that GM-CSF is important in signaling
production of oncostatin M during neutrophil priming as opposed
to during coculture. Similar results were seen with the T47D
human breast cancer cell line.
Cell-to-cell contact is necessary for release of oncostatin M
by neutrophils cocultured with human breast cancer cells. To
assess the amount of oncostatin M stored in neutrophil granules,
cultures were incubated with the peptide FMLP, a peptide known
to stimulate total granular release of neutrophils (30). FMLP (2 
107 mol/L) was added to primed neutrophils, and oncostatin M
levels in the medium were measured over time (15 minutes, 1, 12,
and 24 hours) by ELISA and compared with the amount of
oncostatin M released by neutrophils cocultured with MDA-MB-
231 (Fig. 3A) or T47D (Fig. 3B) human breast cancer cells. At 15
minutes, roughly 93% of total granule-stored oncostatin M was
released by neutrophils cocultured with MDA-MB-231 cells, and
89% by neutrophils cocultured with T47D cells. The percentage of
oncostatin M released was calculated as % oncostatin M released =
[(coculture  MDA-MB-231 or T47D alone) / neutrophils + FMLP] =
[amount released by cocultured neutrophils into medium / total
oncostatin M in neutrophil granules (released by FMLP)]. Over
time, the levels of oncostatin M released into the coculture medium
never dropped below 73% of total granule-oncostatin M (Fig. 3A-B).
To determine if cell-to-cell contact was required for neutro-
phils to release oncostatin M, a transwell assay was done
Figure 2. GM-CSF signals accumulation of oncostatin M
(OSM ) in neutrophils. A, MDA-MB-231 human breast
cancer cells and neutrophils plated with or without
anti-GM-CSF-neutralizing antibody. When neutrophils were
primed for 18 to 24 hours with an anti-GM-CSF-neutralizing
antibody before coculture with MDA-MB-231 human breast
cancer cells, the level of secreted oncostatin M at
15 minutes were equal to control levels, indicating that
GM-CSF is needed for oncostatin M accumulation in
neutrophils. When neutrophils were primed with normal
conditioned medium before coculture and then
anti-GM-CSF-neutralizing antibody was added at the
time of plating, there was only a small decrease in
oncostatin M level as seen by ELISA. Similar results
were obtained when T47D breast cancer cells were
plated with neutrophils (B).
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separating neutrophils from breast cancer cells. The transwells
contained MDA-MB-231 or T47D human breast cancer cells in
the upper chamber. The breast cancer cells could not come into
contact with the primed neutrophils in the bottom chamber,
although the medium could flow freely between the two
chambers. In the transwell culture, no increase of oncostatin
M was detected throughout the time course (Fig. 3C-D)
compared with primed neutrophils cocultured with breast
cancer cells.
Neutrophil-derived oncostatin M induces vascular endothe-
lial growth factor expression in human breast cancer cells.
VEGF is a potent proangiogenic factor and has been implicated
in invasion and metastasis. Coculture of primed neutrophils with
MDA-MB-231 human breast cancer cells showed a modest
increase in secreted VEGF by ELISA (Fig. 4A) compared with
either MDA-MB-231 cells or neutrophils cultured alone. Greatest
levels of secreted VEGF were seen at 3 days (Fig. 4A). T47D human
breast cancer cells cocultured with neutrophils showed a 3.5-fold
Figure 3. Cell-to-cell contact is needed
for granule release of oncostatin M (OSM )
by neutrophils cocultured with human
breast cancer cells. Total granular release
in neutrophils was induced by FMLP
(2  107 mol/L). The level of oncostatin
M released at 15 minutes from primed
neutrophils cocultured with MDA-MB-231
(A) or T47D (B ) cells was f90% of the
total oncostatin M stored in the granules
of neutrophils. Coculture of primed
neutrophils plated in the lower chamber and
MDA-MB-231 (C ) or T47D cells (D ) plated
in the upper chamber and separated by a
3-Am membrane. Separation of the breast
cancer cells from the neutrophils lead to
a decrease in oncostatin M levels (transwell
culture) compared with normal coculture
(coculture), indicating cell-to-cell contact
was needed for release of oncostatin M
by 15 minutes.
Figure 4. Neutrophil-derived oncostatin M
(OSM ) induces VEGF expression. VEGF
ELISA analysis demonstrates an increase
in secreted VEGF by coculture of
neutrophils with MDA-MB-231 (A ) or T47D
(B) human breast cancer cells versus
neutrophils or human breast cancer cells
alone. VEGF secretion peaked at three
days. C-D, neutrophil-derived oncostatin M
signals through the oncostatin M specific
receptor. Neutrophils were cocultured
with MDA-MB-231 (C ) or T47D (D )
human breast cancer cells for 3 days.
Anti-oncostatin M receptor–neutralizing
antibody (0.1 Ag/mL) added to the breast
cancer cells 1 hour before coculture
showed a decrease in VEGF levels,
whereas little decrease in VEGF levels was
seen with the anti-LIFRh-neutralizing
antibody. With the addition of
anti-gp130-neutralizing antibody, VEGF
levels decreased to levels similar to those
with anti-OSMRh. VEGF levels did
not decrease further even when
anti-OSMRh- and anti-LIFRh-neutralizing
antibodies were both added to the
coculture.
Cancer Research
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increase in VEGF levels at days 2 and 3 compared with T47D cells
or neutrophils cultured alone (Fig. 4B). A dose response experiment
was done to determine the anti-oncostatin M–neutralizing
antibody concentration (50 Ag/mL) needed for maximal VEGF
inhibition that did not effect cell proliferation (data not shown).
Anti-oncostatin M–neutralizing antibody added to neutrophils
cocultured with MDA-MB-231 cells resulted in a 52% inhibition of
total VEGF secretion (Supplementary Fig. S1A) and a 57%
inhibition of VEGF secretion when added to T47D cell coculture
(Supplementary Fig. S1B).
To determine whether oncostatin M signals VEGF induction
through the oncostatin M receptor, LIF receptor, or both recep-
tors, we cultured breast cancer cells in the presence of neutra-
lizing antibodies to either OSMRh, LIFRh, or gp130 (a shared
component of both receptors). A 5-fold decrease in VEGF secre-
tion was observed by ELISA when anti-OSMRh-neutralizing anti-
body was added to the MDA-MB-231 coculture system (Fig. 4C),
whereas when the LIFRh-neutralizing antibody was added, there
was little change in VEGF secretion. The addition of gp130-
neutralizing antibody decreased VEGF secretion to levels seen with
anti-OSMRh-neutralizing antibody. When both neutralizing anti-
bodies (anti-OSMRh and anti-LIFRh) were added to the breast
cancer cells, VEGF levels decreased to that of anti-gp130 and anti-
OSMRh alone. Neutralizing antibody concentrations had previously
been optimized at 0.1 Ag/mL (data not shown). Similar results were
seen with T47D coculture system (Fig. 4D).
Neutrophil-derived oncostatin M induces cell detachment
and increases invasive potential of human breast cancer cells.
A decrease in cell-cell and cell-substratum adhesiveness in vitro
has been correlated with increased metastatic potential. We
assessed the effects of neutrophil-derived oncostatin M on the
detachment of MDA-MB-231 and T47D human breast cancer
cells from tissue culture plates. MDA-MB-231 cells cocultured
with primed neutrophils showed a 3-fold increase in viable
detached cell compared with MDA-MB-231 cells cultured alone
(Supplementary Fig. S2A-B). This detachment was largely
inhibited by the addition of anti-oncostatin M–neutralizing
antibody (Supplementary Fig. S2B). Similar results were seen
with cocultured T47D cells (Supplementary Fig. S2C-D).
Oncostatin M released from neutrophils increased the invasive
capacity of human breast cancer cells during coculture as
measured by the Matrigel invasion assay. MDA-MB-231 human
breast cancer cells cocultured with primed neutrophils showed a
2.9-fold increase in invasive capacity (Fig. 5A-B) relative to MDA-
MB-231 cells alone. Similar results were seen with T47D cells
(Fig. 5C-D), which showed a 3-fold increase in invasion when
cocultured with neutrophils. Importantly, oncostatin M–neutraliz-
ing antibody was able to decrease neutrophil-promoted invasive-
ness in cocultures (Fig. 5B-D), which suggests that a large portion
of the increased invasive capacity of cocultured breast cancer cells
results from neutrophil-derived oncostatin M.
Discussion
In this article, we show that (i) resting neutrophils produce
oncostatin M when they are ‘‘primed’’ by breast cancer conditioned
medium; (ii) the signal for oncostatin M synthesis by neutrophils is
breast cancer cell–derived GM-CSF and the release of oncostatin M
is dependent on cell-cell contact; and (iii) neutrophil-derived
oncostatin M induces VEGF expression, breast cancer cell
detachment, and invasive capacity. Oncostatin M is a potent
modulator of inflammation (18, 31, 32). Although oncostatin M was
originally shown to inhibit breast cancer cell (14) and melanoma
cell proliferation in vitro (19), it has more recently been implicated
Figure 5. Neutrophil-derived oncostatin M (OSM ) induces human breast cancer cell invasiveness. A, MDA-MB-231 human breast cancer cells plated alone show
some invasion in the Matigel invasion assay (cells stained blue have invaded through Matrigel), whereas MDA-MB-231 cells show increased invasiveness when
cocultured with primed and anti-oncostatin M–neutralizing antibody decreased invasiveness of MDA-MB-231 cells cocultured with primed neutrophils. B, quantification
of results showed a 3-fold increase in invasive capacity of MDA-MB-231 cells cocultured with primed neutrophils, which was partially abrogated by anti-oncostatin
M–neutralizing antibody. Similar results were obtained when T47D human breast cancer cells were plated with neutrophils (C-D ).
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in angiogenesis and invasion (33). These data, together with the
fact that neutrophils are an important infiltrating cell type in many
types of cancer (34), suggest that neutrophil-derived oncostatin M
could be a promoter of tumor progression and metastasis.
Our immunocytochemistry analyses allowed visualization of
oncostatin M expression in resting (nonstimulated) neutrophils,
primed (activated) neutrophils, and primed neutrophils that had
been cocultured with human breast cancer cells. Oncostatin M
expression was absent or very low in resting neutrophils, somewhat
higher in primed neutrophils, and highest in primed neutrophils
cocultured with human breast cancer cells. It has been previously
shown that oncostatin M is not secreted by resting (nonstimulated)
blood neutrophils, but its expression and secretion are rapidly
activated by proinflammatory signals such as GM-CSF (4).
Oncostatin M secretion occurs through a two-step mechanism
in neutrophils, consisting of early release of preformed stock
oncostatin M in granules followed by de novo protein synthesis
(4). The intracellular stock of preformed oncostatin M in activated
neutrophils is rapidly mobilized by degranulating agents such as
phorbol myristate acetate and GM-CSF (4). In our studies, we used
FMLP in our coculture system to initiate granular release and
found that almost all oncostatin M stored in the neutrophil
granules was released.
GM-CSF is a cytokine that promotes the growth and dif-
ferentiation of cells of monocyte and granulocyte lineages (35).
GM-CSF is produced by many cancer cells types including, colon
(36), prostate (37), and breast (38). GM-CSF has been implicated in
the delay of apoptosis of both neutrophils and lymphocytes and
thus potentially functions to increase the number of neutrophils at
sites of inflammation (39). GM-CSF released by activated
endothelium can act to increase neutrophil survival and function
in the peripheral blood allowing the neutrophil to retain their
functional capabilities (39). High levels or exogenous GM-CSF have
been shown to trigger the release of oncostatin M by neutrophils
(5) and GM-CSF produced by tumor cells, including the metastatic
human breast cancer cell line MDA-MB-231, can alter normal
neutrophil function (29). Lastly, it has been shown that GM-CSF
produced by MDA-MB-231 cells can alter normal neutrophil
function, and these neutrophils can facilitate tumor cell transmi-
gration through the endothelial barrier potentiating the process of
tumor metastasis (38). Grenier et al. (4) did a kinetic study that
showed GM-CSF as a physiologic inducer of not only oncostatin M
synthesis but neutrophil degranulation as well.
We tested whether breast cancer cell–derived GM-CSF was
involved in the activation of resting neutrophils to produce
oncostatin M in our coculture system. We showed an almost
complete abrogation of oncostatin M secretion by cultured
neutrophils when an anti-GM-CSF-neutralizing antibody blocked
GM-CSF during the time of activation (priming). Yet inhibition
of GM-CSF at the time of coculture resulting in only a small
decrease in neutrophil-secreted oncostatin M compared with
normal coculture. Our results concur with Grenier et al. (4) in
Figure 6. Proposed pathway by which
neutrophil-derived oncostatin M (OSM )
leads to increased invasive and metastatic
capacity of human breast cancer cells.
Breast cancer cells supply a signal,
GM-CSF, to neutrophils, which then,
produce oncostatin M and store it in
granules. Cell-to-cell contact between
neutrophil and breast cancer cells causes
neutrophils to release oncostatin M.
Oncostatin M binds to oncostatin M
receptors on the breast cancer cells
signaling increased cell detachment, VEGF
secretion, and invasiveness. Our results
suggest that neutrophils may provide a
source of oncostatin M for cancer cells,
resulting in oncostatin M–induced tumor
progression and metastasis.
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that GM-CSF can activate/prime neutrophils and act as an
important inducer of oncostatin M synthesis.
In this article, we show that inhibition of direct neutrophil-
breast cancer cell contact prevented neutrophil release of stored
oncostatin M from neutrophil granules. A previous study showed
that contact between glioma cells and neutrophils was required
to influence the infiltration of the neutrophils into the tumor
(40). Hor et al. (40) also showed that improved survival of
neutrophils in the presence of glioma cells required cell-to-cell
contact. In addition, our immunocytochemisty results show that
those neutrophils that are in direct contact with breast cancer cells
produce high levels of oncostatin M, whereas little oncostatin M
staining was observed in the f50% of neutrophils that did not
directly associate with breast cancer cells (data not shown).
As neutrophils and mononuclear leukocytes show no expression
of OSMRh or LIFRh (7), and human breast cancer cells (MDA-MB-
231 and T47D) express both OSMRh and LIFRh by Western blot
analysis (data not shown), we believe that neutrophil-derived
oncostatin M primarily acts on breast cancer cells and that
neutrophil-derived oncostatin M is unlikely to work in an autocrine
manner. Therefore, we propose that GM-CSF secreted by breast
cancer cells signals neutrophils to produce and store oncostatin M,
which is then released by neutrophils in response to cell-to-cell
contact with breast cancer cells (Fig. 6). We have yet to identify the
signal needed for oncostatin M release by the neutrophil-breast
cancer cell interaction, although future studies will address this
issue.
Invasive and metastatic capabilities positively correlate with a
decrease in cell-cell and cell-substratum adhesiveness. We showed
a 3-fold increase in MDA-MB-231 and T47D human breast cancer
cell detachment during coculture with neutrophils. We believe
this is largely due to neutrophil-secreted oncostatin M, as anti-
oncostatin M–neutralizing antibodies inhibited >50% of breast
cancer cell detachment. Other neutrophil-secreted factors, such as
VEGF and matrix metalloproteinases (MMP), may also play a role
in cell detachment (2). In addition, we have previously shown that
exogenous oncostatin M is able to induce significant cell
detachment of T47D cells6 and mammary carcinoma cells (20)
from tissue culture plastic, as well as from Matrigel-coated dishes.7
VEGF, a potent proangiogenic factor, plays a crucial role in
tumor angiogenesis, progression, and metastasis. The proangio-
genic effects of VEGF are mostly due to its ability to promote
the survival, proliferation, and motility of endothelial cells (41).
VEGF is produced by endothelial cells (41), vascular smooth
muscle cells (42), monocytes (43), neutrophils (44–46), and breast
cancer cells (47). In this article, we show that coculture of
neutrophils with human breast cancer cells leads to an increase in
VEGF secretion, above the combined amounts released by neu-
trophils or breast cancer cells alone. This VEGF induction is inhi-
bited by anti-oncostatin M–neutralizing antibody indicating that
neutrophil-derived oncostatin M induces VEGF. In addition to
neutrophil-derived oncostatin M (endogenous oncostatin M), our
lab has studied the addition of exogenous recombinant oncostatin
M to human breast cancer cells and observed a similar increase in
oncostatin M-induced VEGF.5 Here we show an increase in VEGF
expression by 2 to 3 days, whereas neutrophil-released oncostatin
M was highest at 15 minutes. These results are in agreement with
the time course of exogenous oncostatin M treatment previously
done in our lab.5 Increased levels of VEGF in a tumor environment
disrupt the neutral balance of proangiogenic and antiangiogenic
factors, initiating angiogenesis and promoting growth, mainte-
nance, and metastasis of solid tumors.
We have shown that the increase in VEGF secretion by breast
cancer cells is the result of oncostatin M binding to the OSMR on
breast cancer cells and that the LIFR is not important. Similar results
have also been shown using astroglioma cells (33). We predict that
neutrophil-derived oncostatin M will signal VEGF induction
through the JAK-STAT pathway, as we have previously shown
using exogenous oncostatin M treatment of human breast cancer
cell lines5 and others have shown with astroglioma cell lines (33).
Invasive capabilities of breast cancer cells are positively correlated
with an increase in protease expression and VEGF expression and a
decrease in cell-cell and cell-substratum attachment (20). Because
we observed both increased cell detachment and increased VEGF
expression by breast cancer cells in our coculture system, we
investigated breast cancer cell invasive potential. We showed an
increase in invasive capacity for both MDA-MB-231 cells (324%)
and T47D cells (420%) when cocultured with primed neutrophils.
Anti-oncostatin M–neutralizing antibody inhibited invasiveness
of cocultured breast cancer cells, suggesting a role for neutro-
phil-derived oncostatin M. The addition of anti-oncostatin
M–neutralizing antibody did not completely inhibit breast cancer
cell invasive capacity, suggesting that neutrophil-derived oncos-
tatin M may not be solely responsible for the increased invasive-
ness seen in our cocultures. Other neutrophil-derived factors may
contribute to the increased invasion of cocultured breast cancer
cells, including MMPs (48) and cathepsins (9).
In other systems, oncostatin M has been shown to induce
transmigration of human neutrophils through monolayers of
endothelial cells by stimulating endothelial cells to express adhesion
molecules and chemokines (18). Wu et al. (29) have shown that
tumor-conditioned medium isolated from the human breast cancer
cell line MDA-MB-231 alters normal human neutrophil function by
suppressing the cytocidal capacity of neutrophils and at the same
time increasing expression of neutrophil adhesion receptors.
In conclusion, our studies show that neutrophil-derived
oncostatin M is involved in VEGF induction, breast cancer cell
detachment, and increased invasiveness (Fig. 6). Based on our
data, neutrophils could be a possible target for the inhibition of
tumor progression and metastasis. Ultimately, developing leuko-
cyte inhibitory therapies could be a useful approach for treatment
of invasive cancers with infiltrating neutrophils. Future work will
be directed towards investigating the mechanism of cell-to-cell
contact required for the release of neutrophil-derived oncostatin M,
as well as assessing the significance of neutrophil-derived
oncostatin M in human breast cancer progression and metastasis
in vivo .
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